Gastroenterology Licensing Deal Benchmarks 2026

Gastroenterology has emerged as one of the most dynamic licensing areas in biopharma, fueled by the validation of novel targets like TL1A and the continued expansion of IL-23 and integrin pathways. The Merck/Prometheus Biosciences acquisition at $10.8B for anti-TL1A set a transformative valuation benchmark for the GI space. Phase 2 anti-TL1A deals for Crohn's disease carry a median total deal value of $3.3B, while IL-23 approaches to UC reach $3.0B.

GI deal structures reflect the chronic nature of IBD treatment (lifelong therapy), large patient populations (3M+ US IBD patients), and well-defined clinical endpoints (endoscopic remission, clinical remission). The growing focus on combination approaches (IL-23 + TL1A, biologics + JAK inhibitors) is driving platform deal interest. EoE deals average $2.9B as dupixent validated the eosinophilic pathway.

Royalty rates across GI licensing range from 8.1% to 15.1% at the base tier. Key valuation drivers include differentiation versus adalimumab and vedolizumab, oral versus injectable formulation, mucosal healing rates, and potential for steroid-free remission. The biosimilar erosion of adalimumab (Humira) has created opportunity for next-generation targeted therapies with superior efficacy profiles.